David Steinberg is a General Partner at Longwood Fund. He is currently Chairman of the Board of Longwood portfolio companies Photys Therapeutics and Be Biopharma, where he also served as founding Chief Executive Officer, and serves on the board of Longwood portfolio companies AAVantgarde Bio, Carbon Biosciences, Lassen Therapeutics, and Rectify Pharmaceuticals.
Previously, he was co-founder and Chief Innovation Officer of biotech venture creation firm PureTech Health (NASDAQ: PRTC), focusing on launching and investing in innovative biotech companies. David was the co-founder and CEO of several biotech companies, including Longwood-founded companies Pyxis Oncology (NASDAQ:PYXS) , Photys Therapeutics, Be Biopharma, and Carbon Biosciences as well as co-founder and CEO of Vor Biopharma (NASDAQ: VOR), Vedanta Biosciences, and Calix, and co-founder of Restorbio (NASDAQ:TORC). He previously worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and R&D at P&G Pharmaceuticals.
David received his MBA in strategy and finance from the University of Chicago Booth School of Business and holds a BA in biology from Cornell University.